nSummary of clinical trials at Marsden Eye Research Centre
At Marsden eye specialists we value the importance of evidence based research in probing for new treatments to various eye conditions. We have been involved in numerous international and local clinical trials in areas of Age-related macular degeneration (AMD), Diabetic macular edema (DME), Retinal vein occlusions (RVO) and Glaucoma. Patients enrolled in these trials have access to new advanced treatment that are in the final stages of development prior to approval and release. Our clinical research team comprises of Opthalmologists, Orthoptists and Nurses.
Our Research Team
Dr Jennifer Arnold – Head of Research, Principal Investigator and Sub Investigator (AMD, DME, BRVO, CRVO trials)
Dr Ashish Agar – Principal Investigator (Glaucoma trials)
Dr Terence Tan – Principal Investigator and Sub Investigator (AMD, DME, BRVO, CRVO trials)
Dr Samuel Dance - Principal Investigator and Sub Investigator (AMD, DME, BRVO, CRVO trials)
Dr Helene Cass – Principal Investigator and Sub Investigator (AMD, DME, BRVO, CRVO trials)
Clinical Trials Coordinators -Trish Forsyth and Charly Jane Hanrahan
Orthoptists- Ivy Chow, Mitchell Bagley, Pelin Cildiroglu, Narendran Kumaraselvam, Harman Singh
Trial Nurses - Julie Boland, Don Tolentino
Current Trials Recruiting:
Wet AMD
- KIRIN AMD– A phase 2 study of VEGF inhibitor eyedrops after 3 doses Of Aflibercept IVT
- LUCIA – Commencing Late April 2025, A phase 3 study of a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept commencing May 2025
- SOL-R - A Phase 3 Intravitreal OTK-TKI (axitinib implant) in subjects with Wet AMD commencing May 2025
Diabetes
- KIRIN DME– A phase 2 study of VEGF inhibitor eyedrops after 5 doses Of Aflibercept IVT
- BRUNELLO– A phase 2/3 of EYE103 Compared with Intravitreal ranibizumab (0.5mg) in Participants with Diabetic Macular Edema
- VANTAGE – A Phase 2 study to evaluate the efficacy and safety of orally administered VX-01 in diabetic retinopathy of Non proliferative type (NPDR)
- THN391-OPT-101- A Phase 1b Open-Label, Multiple Ascending Dose Study of the Safety, Tolerability, and Biological Activity of Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non Proliferative Diabetic Retinopathy
- SPECTRUM- An observational study program to investigate the effectiveness of Aflibercept 8 mg used in DME and nAMD in a real-world setting
Geographic Atrophy trials
- ARCHERII- A phase 3 Multicenter, Double-Masked, 2 Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Retinal Vein Occlusions
- No recruiting trials at present
Please contact Clinical Trials Co-ordinator Trish Forsyth on or email enquiry@marsdeneye.com if you would like further information.